Xeris Biopharma (NASDAQ:XERS) Insider Sells $133,827.98 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total value of $133,827.98. Following the completion of the sale, the insider directly owned 1,161,128 shares in the company, valued at approximately $9,323,857.84. This represents a 1.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Monday, June 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.06, for a total value of $101,002.02.
• On Friday, May 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.23, for a total value of $103,835.41.

Xeris Biopharma Price Performance

Xeris Biopharma stock traded up $0.28 during midday trading on Thursday, reaching $8.28. The company’s stock had a trading volume of 3,703,283 shares, compared to its average volume of 1,901,927. Xeris Biopharma Holdings, Inc. has a 52 week low of $4.62 and a 52 week high of $10.08. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. The business has a 50-day moving average price of $6.51 and a 200-day moving average price of $6.61. The stock has a market cap of $1.43 billion, a PE ratio of 138.00 and a beta of 0.62.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The firm had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. On average, sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Hedge Funds Weigh In On Xeris Biopharma

Large investors have recently modified their holdings of the business. UBS Group AG lifted its holdings in shares of Xeris Biopharma by 682.4% during the third quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after purchasing an additional 1,554,869 shares during the period. Vanguard Group Inc. increased its holdings in Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after purchasing an additional 1,358,760 shares during the period. Qube Research & Technologies Ltd raised its position in Xeris Biopharma by 67.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after purchasing an additional 1,245,188 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Finally, Granahan Investment Management LLC lifted its holdings in Xeris Biopharma by 249.4% during the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after buying an additional 873,236 shares during the period. Institutional investors own 42.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.